Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
Differing trends in the incidence of vascular comorbidity in MS and the general population.
Multiple sclerosis and risk of attempted and completed suicide - a cohort study.
Genetic analysis of aquaporin-4 in neuromyelitis optica.
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Full Prescribing Information, Copaxone (glatiramer acetate)
The pathogenesis of demyelinating form of Guillain-Barre syndrome: proteo-peptidomic and immunological profiling of physiological fluids.
Dimethylfumarate induces apoptosis in human mast cells.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Differences in the burden of psychiatric comorbidity in MS vs the general population.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.
BRIEF: Teva files for Copaxone-Laquinimod patent

Pages